Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Sep 21, 2017 in Leukemia | 0 comments

In a nutshell

This study examined the safety and effectiveness of pembrolizumab in the treatment of chronic lymphocytic leukemia that has undergone Richter’s transformation. This study concluded that patients with Richter’s transformation responded to pembrolizumab

Some background

Chronic lymphocytic leukemia is a cancer where the bone marrow makes too many lymphocytes (white blood cells). Some patients do not respond to initial treatment and the leukemia progresses. They can develop Richter’s transformation, which is a transformation into an aggressive cancer that can lead to poorer outcomes.

Pembrolizumab (Keytruda) is a treatment that blocks a protein (PD-1) present on many cancer cells. This can lead the immune system to attack the cells. Pembrolizumab is often used in lung cancer, skin cancer and Hodgkin’s lymphoma. It is suggested that pembrolizumab would be effective in chronic lymphocytic leukemia that has relapsed (cancer that has returned) or has undergone Richter’s transformation. 

Methods & findings

16 patients with relapsed or refractory (not responding to treatment) chronic lymphocytic leukemia and 9 patients with Richter’s transformation were studied. Patients received an average 3 cycles of pembrolizumab. The average length of treatment was 7.5 weeks for patients with chronic lymphocytic leukemia and 13 weeks for patients with Richter’s transformation. Patients were followed-up for an average 10.4 months.

The average overall survival (time from treatment until death from any cause) for all patients was 10.7 months. 44% of patients with Richter transformation responded to pembrolizumab. Of these, one patient achieved a complete response to pembrolizumab (no evidence of disease). Three patients achieved a partial response, four patients had stable disease, and one saw disease progression. Patients with chronic lymphocytic leukemia and no Richter’s transformation stopped pembrolizumab treatment because there was no response. 

All patients experienced negative side effects. 60% of patients had a severe adverse event. 20% of patients had low levels of white blood cells and 20% of patients had low red blood cells which was caused by treatment.  8% of patients had shortness of breath. 

The bottom line

This study concluded taht patients with chronic lymphocytic leukemia who underwent Richter’s transformation responded to pembrolizumab

The fine print

There was a small number of patients studied. Further studies are necessary. 

Published By :

Blood

Date :

Apr 19, 2017

Original Title :

Pembrolizumab in patients with chronic lymphocytic leukemia with Richter’s transformation and relapsed CLL.

click here to get personalized updates